Characterizing genetic variants for clinical action.
Loading...
Embargo End Date
ICR Authors
Authors
Ramos, EM
Din-Lovinescu, C
Berg, JS
Brooks, LD
Duncanson, A
Dunn, M
Good, P
Hubbard, TJP
Jarvik, GP
O'Donnell, C
Sherry, ST
Aronson, N
Biesecker, LG
Blumberg, B
Calonge, N
Colhoun, HM
Epstein, RS
Flicek, P
Gordon, ES
Green, ED
Green, RC
Hurles, M
Kawamoto, K
Knaus, W
Ledbetter, DH
Levy, HP
Lyon, E
Maglott, D
McLeod, HL
Rahman, N
Randhawa, G
Wicklund, C
Manolio, TA
Chisholm, RL
Williams, MS
Din-Lovinescu, C
Berg, JS
Brooks, LD
Duncanson, A
Dunn, M
Good, P
Hubbard, TJP
Jarvik, GP
O'Donnell, C
Sherry, ST
Aronson, N
Biesecker, LG
Blumberg, B
Calonge, N
Colhoun, HM
Epstein, RS
Flicek, P
Gordon, ES
Green, ED
Green, RC
Hurles, M
Kawamoto, K
Knaus, W
Ledbetter, DH
Levy, HP
Lyon, E
Maglott, D
McLeod, HL
Rahman, N
Randhawa, G
Wicklund, C
Manolio, TA
Chisholm, RL
Williams, MS
Document Type
Journal Article
Date
2014-03-13
Date Accepted
Abstract
Genome-wide association studies, DNA sequencing studies, and other genomic studies are finding an increasing number of genetic variants associated with clinical phenotypes that may be useful in developing diagnostic, preventive, and treatment strategies for individual patients. However, few variants have been integrated into routine clinical practice. The reasons for this are several, but two of the most significant are limited evidence about the clinical implications of the variants and a lack of a comprehensive knowledge base that captures genetic variants, their phenotypic associations, and other pertinent phenotypic information that is openly accessible to clinical groups attempting to interpret sequencing data. As the field of medicine begins to incorporate genome-scale analysis into clinical care, approaches need to be developed for collecting and characterizing data on the clinical implications of variants, developing consensus on their actionability, and making this information available for clinical use. The National Human Genome Research Institute (NHGRI) and the Wellcome Trust thus convened a workshop to consider the processes and resources needed to: (1) identify clinically valid genetic variants; (2) decide whether they are actionable and what the action should be; and (3) provide this information for clinical use. This commentary outlines the key discussion points and recommendations from the workshop.
Citation
American journal of medical genetics. Part C, Seminars in medical genetics, 2014, 166C (1), pp. 93 - 104
Source Title
Publisher
ISSN
1552-4868
eISSN
1552-4876
Research Team
Genetic Susceptibility